Finally, the ADAURA trial investigated the use of osimertinib as an adjuvant treatment in patients with resected NSCLC stage IB to IIIA harboring EGFR mutations, and the results demonstrated significantly longer disease-free survival compared with the placebo, resulting in the approval of the drug in the adjuvant setting [8] (Figure 1). Here, EGFR is linked to non-small cell lung carcinoma.